We appreciate Daniele Giacobbe’s Correspondence regarding the importance of colistin minimum inhibitory concentrations.
A study showed that both gradient-based and semi-automated devices can overestimate susceptibility to colistin. [...]

doi.org/10.1016/S1473-3099(18)30223-8, hdl.handle.net/1765/105899
The Lancet Infectious Diseases
Department of Medical Microbiology and Infectious Diseases

Paul, M, Carmeli, Y, Daikos, G.L, Durante-Mangoni, E, Theuretzbacher, U, Mouton, J.W, & Leibovici, L. (2018). Colistin versus colistin plus meropenem for severe infections: Authors' reply. The Lancet Infectious Diseases, 18(5), 495–496. doi:10.1016/S1473-3099(18)30223-8


See Also
article
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria
M. Paul (Mical), G.L. Daikos (George), E. Durante-Mangoni (Emanuele), Yahav, D. (Dafna), Y. Carmeli (Yehuda), Benattar, Y.D. (Yael Dishon), Skiada, A. (Anna), Andini, R. (Roberto), Eliakim-Raz, N. (Noa), Nutman, A. (Amir), et al. Zusman, O. (Oren), A. Antoniadou (A.), Pafundi, P.C. (Pia Clara), Adler, A. (Amos), Dickstein, Y. (Yaakov), Pavleas, I. (Ioannis), Zampino, R. (Rosa), Daitch, V. (Vered), Bitterman, R. (Roni), Zayyad, H. (Hiba), Koppel, F. (Fidi), Levi, I. (Inbar), Babich, T. (Tanya), L.E. Friberg (Lena), J.W. Mouton (Johan), U. Theuretzbacher (Ursula) and L. Leibovici (Leonard)